|Application ||IHC-P, IF, FC|
|Other Accession||3856, 533782, 708445|
|Isotype||Mouse / IgG1, kappa|
|Other Names||Keratin, type II cytoskeletal 8, Cytokeratin-8, CK-8, Keratin-8, K8, Type-II keratin Kb8, KRT8, CYK8|
|Format||200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||Cytokeratin 8 (KRT8) Antibody - Without BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Together with KRT19, helps to link the contractile apparatus to dystrophin at the costameres of striated muscle.|
|Cellular Location||Cytoplasm. Nucleus, nucleoplasm Nucleus matrix|
|Tissue Location||Observed in muscle fibers accumulating in the costameres of myoplasm at the sarcolemma membrane in structures that contain dystrophin and spectrin. Expressed in gingival mucosa and hard palate of the oral cavity.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Epitope of this MAb is located between aa343-357 (ELAIKDANAKLSELE). Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Reportedly, anti-CK8 is useful for the differentiation of lobular (�ring-like, perinuclear�) from ductal (�peripheral-predominant�) carcinoma of the breast.
Guelstein VI et. al. Int J Cancer 42:147-53 (1988). Diversity in immunoreactivity of tumor-derived cytokeratin monoclonal antibodies. J. Histochem. Cytochem., 37: 1845-1854 (1989). | Epitope Specificity of the Monoclonal Anticytokeratin Antibody TS1. Cancer Research, 59: 48-51, (1999). | Epitope Specificity of 30 Monoclonal Antibodies against Cytokeratin Antigens: The ISOBM TD5-1 Workshop. Tumor Biology 19: 132-152, (1998). | Immunohistochemical Profiles of 30 Monoclonal Antibodies against Cytokeratins 8, 18 and 19. Tumor Biology 19: 4-10, (1998)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.